Filing Details

Accession Number:
0001209191-19-046448
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-19 07:38:19
Reporting Period:
2019-08-16
Accepted Time:
2019-08-19 07:38:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1123494 Harvard Bioscience Inc HBIO Laboratory Analytical Instruments (3826) 043306140
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1400121 W James Green C/O Harvard Bioscience, Inc.
84 October Hill Road
Holliston MA 01746
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-08-16 10,000 $2.49 1,525,404 No 4 P Indirect by James W. Green Revocable Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect by James W. Green Revocable Trust
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $2.47 to $2.50, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 202,875 restricted stock units which shall fully vest on July 8, 2020; (c) a deferred stock award of 243,072 restricted stock units which shall fully vest on July 8, 2021; (d) a deferred stock award of 418,360 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (e) a deferred stock award of 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 207,637 shares of common stock beneficially owned by the Reporting Person.